Aultman Hospital Adds Layer of Safety with Evolv Technology

AI-Powered Weapons Detection Integrates With Hospital’s Genetec Technology

Evolv Technology (NASDAQ: EVLV), the leader in AI-based weapons detection security screening, today announced its partnership with Aultman Hospital in Ohio. The hospital will use Evolv’s state-of-the-art Evolv Express® screening solution at two high-traffic areas in the building.

Evolv Express uses powerful sensor technology with artificial intelligence (AI) to provide safer, more accurate threat detection at unprecedented volume and speed. Aultman Hospital, located in Canton, Ohio, will use two systems– one at its main entrance and another for its emergency department.

“We needed a weapons detection solution that wouldn’t impact people trying to get to work or to an appointment, and Evolv was the perfect answer,” said Darin B. Baad, security coordinator at Aultman Hospital. “Unfortunately, hospitals are facing increased levels of violence, and we need to take steps to protect our environment without stopping and checking every person individually as they walk in.”

Evolv Express allows people to move through security screening without having to always open bags or empty pockets, preventing backups at entrances. The technology distinguishes between threats and most everyday items people carry. According to Aultman Hospital, within the first ten hours of installing the new systems, a number of prohibited items were found, including a gun, a taser, and knives, and nurses and staff have praised the hospital for prioritizing safety.

Aultman procured its Evolv Express systems from Johnson Controls, an Evolv distribution partner. Evolv’s Genetec integration also allows the technology to work seamlessly with the other security measures Aultman Hospital has in place, including security cameras and access control.

“This is an exciting partnership because Aultman Hospital is the first to take advantage of Evolv’s Genetec integration capability,” said Jason Grellner, vice president, healthcare for Evolv. “More and more hospitals are looking to add weapons detection screening for their facilities, and we believe Evolv will help provide some peace of mind to patients, doctors, nurses, and hospital staff.”

Aultman Hospital joins a number of other healthcare facilities using Evolv as they strive to create a safer environment for patients, visitors and staff and respond to the growing concern healthcare workers face when it comes to workplace violence.

About Evolv Technology

Evolv Technology (NASDAQ: EVLV) is transforming human security to make a safer, faster, and better experience for the world’s most iconic venues and companies as well as schools, hospitals, and public spaces, using industry leading artificial intelligence (AI)-powered weapons detection and analytics. Its mission is to transform security to create a safer world to work, learn, and play. Evolv has digitally transformed the gateways in places where people gather by enabling seamless integration combined with powerful analytics and insights. Evolv’s advanced systems have scanned more than 600 million people, second only to the Department of Homeland Security’s Transportation Security Administration (TSA) in the United States. Evolv has been awarded the U.S. Department of Homeland Security (DHS) SAFETY Act Designation as a Qualified Anti-Terrorism Technology (QATT) as well as the Security Industry Association (SIA) New Products and Solutions (NPS) Award in the Law Enforcement/Public Safety/Guarding Systems category. Evolv Technology®, Evolv Express®, Evolv Insights®, and Evolv Cortex AI® are registered trademarks of Evolv Technologies, Inc. in the United States and other jurisdictions. For more information, visit https://evolvtechnology.com.

Forward-looking Statements

Certain statements in this press release may constitute “forward-looking��� statements and information, within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 that relate to our current expectations and views of future events. In some cases, these forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect our current views with respect to future events or our Company’s performance and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation, the risk factors set forth in our Annual Report on Form 10-K for the year ended on December 31, 2022, that was filed with the SEC on March 24, 2023, as may be updated in other filings we make with the SEC, including our Quarterly Report on Form 10-Q for the quarter ended on March 31, 2023 that was filed with the SEC on May 10, 2023. These statements reflect management’s current expectations regarding future events and operating performance and speak only as of the date of this press release. You should not put undue reliance on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230719726322/en/